射干组分制剂对临床常见耐药菌体外抑菌及血清药理学试验研究  

In Vitro Bacteriostatic and Serum Pharmacological Tests of Pardanthus Component Preparation on Clinically Common Drug-Resistant Bacteria

作　　者：尹江涛 张颖 赵玥 王秋野 李国信[1] 关玉娟[1] 于雪峰[1] 汪天青 YIN Jiangtao;ZHANG Ying;ZHAO Yue;WANG Qiuye;LI Guoxin;GUAN Yujuan;YU Xuefeng;WANG Tianqing(The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine/Liaoning Institute of Traditional Chinese Medicine,Shenyang 110034,Liaoning,China)

机构地区：[1]辽宁中医药大学附属第二医院,辽宁省中医药研究院,辽宁沈阳110034

出　　处：《中华中医药学刊》2022年第4期234-238,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：辽宁省自然科学基金指导计划(2019-ZD-0841);辽宁省教育厅“育苗基金”计划(L201925);辽宁省科技厅省重点研发计划(2020JH2/10300090);辽宁省博士启动科学基金(2019-BS-144);沈阳市科学技术计划(21-173-9-57)。

摘　　要：目的射干组分制剂为射干抗炎、止咳有效成分单体的复合制剂,应用射干组分制剂及大鼠含药血清联合抗生素进行体外抑菌及血清药理学实验研究,观察及评价射干组分制剂对临床常见耐药菌的体外抑菌作用。方法制备5种不同浓度射干组分制剂混悬液及射干含药血清,并对耐甲氧西林金黄色葡萄球菌(methicillin-resistant staphylococcus aureus,MRSA)、多重耐药铜绿假单胞菌(CR-PA)、多重耐药鲍曼不动杆菌(CR-AB)进行体外抑菌实验及血清药理学实验。结果体外抑菌实验表明8倍给药量对MRSA、CR-PA与CR-AB抑菌率达100%、99.66%和93.98%;哌拉西林钠他唑巴坦对MRSA的最小抑菌浓度为128μg/mL,128μg/mL哌拉西林钠他唑巴坦仍无法完全抑制CR-PA与CR-AB生长;当8倍含药血清作用于MRSA、CR-PA与CR-AB时,细菌未见生长;当含药血清与哌拉西林钠他唑巴坦联合应用作用于MRSA、CR-PA与CR-AB时,最小抑菌浓度分别为2倍+16μg/mL、8倍+64μg/mL、4倍+32μg/mL。结论高浓度射干组分制剂体外可完全抑制MRSA生长,CR-PA与CR-AB对高浓度射干组分制剂有较强敏感性,但射干组分制剂体外不能完全抑制CR-PA与CR-AB生长;射干组分制剂含药血清能明显提高哌拉西林钠他唑巴坦的抑菌作用。Objective Pardanthus component preparation is a compound preparation of anti-inflammatory and anti-cough active component monomer.In vitro bacteriostasis and serum pharmacology experiments were carried out by using pardanthus component preparation and rat serum containing drugs combined with antibiotics to observe and evaluate the in vitro bacteriostatic effect of pardanthus component preparation on common clinical drug-resistant bacteria.Methods Five different concentrations of suspension pardanthus component preparation and serum containing pardanthus component preparation were prepared,and the in vitro bacteriostatic test and serum pharmacological test of MRSA,Cr-PA and Cr-Ab were carried out.Results In vitro bacteriostatic experiments showed that the bacteriostatic rates of MRSA,Cr-PA and Cr-Ab were 100%,99.66%and 93.98%after 8 times of dosage.The minimal inhibitory concentration of piperacillin sodium tazobactam against MRSA was 128μg/mL,and the growth of Cr-PA and Cr-Ab could not be completely inhibited by piperacillin sodium tazobactam.No bacterial growth was observed when 8 times of drug-containing serum was treated with MRSA,Cr-PA and Cr-Ab.When the drug containing serum was combined with piperacillin sodium tazobactam on MRSA,Cr-PA and Cr-Ab,the minimal inhibitory concentrations were 2 times+16μg/mL,8 times+64μg/mL and 4 times+32μg/mL,respectively.Conclusion Cr-PA and Cr-Ab had strong sensitivity to the high concentration of pardanthus component preparation,but could not completely inhibit the growth of Cr-PA and Cr-Ab in vitro.The anti-fungal activity of piperacillin sodium and tazobactam was significantly improved in the serum containing pardanthus component preparation.

关 键 词：射干组分制剂 抗生素 体外抑菌 血清药理学 耐药菌 

分 类 号：R285.5[医药卫生—中药学]